ArticleIndian journal of surgical oncology2025
Circumscribed Pilocytic Astrocytoma Including Pilomyxoid and Intermediate Pilomyxoid Variants - A Single Institutional, Retrospective Study.
Article in Indian journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Classical pilocytic astrocytoma (PA) is the most common childhood glioma that corresponds to WHO Grade I. These tumors are generally well circumscribed and are also observed in adult population. Due to diverse histomorphological patterns, a subtype was added by WHO in 2007 that was referred to as pilomyxoid astrocytoma (PMA). Initially, it was thought that the clinical behavior of PMA was more aggressive. Recent WHO classification (2021) has, however, not assigned a grade to PMA due to insufficient data in medical literature. Fourteen cases of PA, four cases of PMA, and two cases of intermediate pilomyxoid tumor (IPMT) constituted the study group. Majority of the patients were in pediatric age group (PA 78%; PMA 100%), mean age of PMA was 10 years vs PA was 16 years. Cerebellum was the commonest location for both PA and PMA. Tumor dimension greater than 5 cm was noted in 57% PA cases and 50% PMA cases. Solid-cystic mass lesion was observed in 86% PAs and 75% PMAs. IPMT tumor with dual morphology was noted, one each in pediatric and adult patient. Gross total resection of the tumor was achievable in 78% and 75% of PA and PMA, respectively. Follow-up duration ranged from 6 to 180 months, and recurrence was noted in 2 PA patients and one PA patient died after 1 year of treatment. Despite the varied morphological features of PA and PMA, considerable overlap was noted in clinico-radiological behavior, postoperative outcome, certain morphological parameters, and immunomarker expression in tumor cells among the two subtypes. Designating PMA as a higher grade tumor cannot be justified presently; additional multidisciplinary studies are needed for final decisiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.